Arcellx Future Growth

Future criteria checks 2/6

Arcellx is forecast to grow earnings and revenue by 3.7% and 21.6% per annum respectively. EPS is expected to grow by 5.1% per annum. Return on equity is forecast to be -9.8% in 3 years.

Key information

3.7%

Earnings growth rate

5.1%

EPS growth rate

Biotechs earnings growth	24.4%
Revenue growth rate	21.6%
Future return on equity	-9.8%
Analyst coverage	Good
Last updated	10 Apr 2024

Recent future growth updates

Arcellx, Inc. (NASDAQ:ACLX) Just Reported And Analysts Have Been Lifting Their Price Targets

Mar 01

Recent updates

Arcellx, Inc. (NASDAQ:ACLX) Just Reported And Analysts Have Been Lifting Their Price Targets

Mar 01

Arcellx: Navigating The CAR T-Cell Revolution

Jan 30

Need To Know: Analysts Are Much More Bullish On Arcellx, Inc. (NASDAQ:ACLX) Revenues

Nov 18

Earnings Miss: Arcellx, Inc. Missed EPS And Analysts Are Revising Their Forecasts

May 10

Earnings and Revenue Growth Forecasts

NasdaqGS:ACLX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	89	-143	-72	-38	7
12/31/2025	102	-122	-96	-88	13
12/31/2024	86	-106	-84	16	13
12/31/2023	110	-71	186	208	N/A
9/30/2023	47	-130	104	122	N/A
6/30/2023	32	-183	105	115	N/A
3/31/2023	18	-190	113	115	N/A
12/31/2022	N/A	-189	-102	-99	N/A
9/30/2022	N/A	-170	-99	-93	N/A
6/30/2022	N/A	-95	-94	-89	N/A
3/31/2022	N/A	-80	-83	-77	N/A
12/31/2021	N/A	-65	-60	-54	N/A
9/30/2021	N/A	-53	-42	-40	N/A
12/31/2020	N/A	-32	-30	-29	N/A
12/31/2019	N/A	-18	-23	-19	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ACLX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ACLX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ACLX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ACLX's revenue (21.6% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: ACLX's revenue (21.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ACLX is forecast to be unprofitable in 3 years.

Arcellx Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus revenue estimates increase by 10%

Price target increased by 13% to US$75.92

Arcellx, Inc. (NASDAQ:ACLX) Just Reported And Analysts Have Been Lifting Their Price Targets

Price target increased by 10.0% to US$72.27

Price target increased by 8.5% to US$65.18

Price target increased by 9.5% to US$56.55

Recent updates

Chief Medical Officer exercised options and sold US$818k worth of stock

Arcellx, Inc., Annual General Meeting, May 24, 2024

Independent Director notifies of intention to sell stock

Consensus revenue estimates increase by 10%

Price target increased by 13% to US$75.92

Arcellx, Inc. (NASDAQ:ACLX) Just Reported And Analysts Have Been Lifting Their Price Targets

Price target increased by 10.0% to US$72.27

Chairman of the Board recently sold US$2.4m worth of stock

New major risk - Revenue and earnings growth

Chairman of the Board notifies of intention to sell stock

Arcellx: Navigating The CAR T-Cell Revolution

Chairman of the Board recently sold US$1.6m worth of stock

Chairman of the Board notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Price target increased by 8.5% to US$65.18

Arcellx, Inc. Announces Continued Robust Long-Term Responses from its Cart-Ddbcma Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma At Ash

Need To Know: Analysts Are Much More Bullish On Arcellx, Inc. (NASDAQ:ACLX) Revenues

Arcellx, Inc. announced that it expects to receive $199.999991 million in funding from Gilead Sciences, Inc.

Price target increased by 9.5% to US$56.55

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 11%

Arcellx, Inc. Announces Oral Presentation for CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma At the 65th ASH Annual Meeting and Exposition

Consensus revenue estimates fall by 47%

Arcellx, Inc. Announces Partial Clinical Hold Lifted on Immagine-1 Phase 2 Clinical Program

Arcellx, Inc. Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program

Chairman of the Board recently sold US$115k worth of stock

Consensus EPS estimates fall by 365%

Price target increased by 12% to US$47.56

Earnings Miss: Arcellx, Inc. Missed EPS And Analysts Are Revising Their Forecasts

Price target increased by 9.2% to US$43.56

Chief Medical Officer notifies of intention to sell stock

Price target increased by 7.9% to US$42.33

Chief Medical Officer exercised options and sold US$404k worth of stock

Chief Medical Officer notifies of intention to sell stock

Arcellx, Inc. announced that it has received $100.000004 million in funding from Gilead Sciences, Inc.

Insider recently sold US$51k worth of stock

Insider recently sold US$51k worth of stock

Chief Medical Officer exercised options and sold US$231k worth of stock

Arcellx, Inc. Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress

Companies Like Arcellx (NASDAQ:ACLX) Are In A Position To Invest In Growth

High number of new directors

Arcellx: The Best Is Yet To Come

Arcellx, Inc. announced delayed 10-Q filing

Arcellx GAAP EPS of -$0.88

Arcellx down 9% on day lock-up period ends

We're Hopeful That Arcellx (NASDAQ:ACLX) Will Use Its Cash Wisely

Arcellx, Inc.(NasdaqGS:ACLX) dropped from Russell 2000 Growth Index

Arcellx: Speculative Buy For Their 'Best-In-Class' CAR-T Cell Therapy

Arcellx, Inc. Announces New Positive Clinical Data from the Ongoing Phase 1 Expansion Study of Its Novel, Autologous, CART-ddBCMA Therapy

High number of new directors

Arcellx, Inc. Appoints Michelle Gilson as Chief Financial Officer

Arcellx, Inc. Announces Resignation of Lewis T. Williams from Board of Directors

Arcellx Announces Dosing of First Patient in its Phase 1 Clinical Trial Evaluating ACLX-001, the First Therapeutic in the Dosable and Controllable ARC-SparX Platform, for the treatment of Patients with Relapsed or Refractory Multiple Myeloma

Arcellx Announces Publication in Blood Advances of Clinical Results from the Dose Escalation Cohorts of its CART-ddBCMA Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma

High number of new directors

Arcellx, Inc. Presents Pre-Clinical Data for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid Leukemia at the American Association for Cancer Research Annual Meeting

Arcellx Announces Pre-Clinical Data Presentation for ACLX-002 at the American Association for Cancer Research Annual Meeting 2022

High number of new directors

Arcellx, Inc. has completed an IPO in the amount of $123.75 million.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies